McKesson Recalls Aspirin DR Tablets for Dissolution Failure
McKesson Packaging Services is recalling Aspirin DR Enteric Coated Tablets because they failed to meet dissolution specifications at the 12-month time interval.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class III, which indicates the product is not likely to cause adverse health consequences. The failure is a quality specification issue (dissolution) without reported injuries or illnesses, fitting the criteria for a moderate severity score.
Plain-English summary
McKesson Packaging Services is recalling Aspirin DR Enteric Coated Tablets, USP 325 mg. The recall involves 1,511,250 tablets distributed nationwide under Lot 0093943.
The recall was initiated because the product failed to meet the required dissolution specification at the 12-month time interval. This means the tablets may not release the medication as intended over time.
Consumers with this specific lot of Aspirin DR should stop using the product and contact their pharmacist or McKesson Packaging Services for further instructions or a refund.
The recalled product
- Product
- Aspirin DR Enteric Coated Tablets, USP 325 mg, UD 750 tablets (25x30), Dist. By: McKesson Packaging Services a business unit of McKesson Corporation, concord, NC
- Manufacturer
- Mckesson Packaging Services
- Affected units
- 1,511,250
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot 0093943
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Mckesson Packaging Services
See all →- ModerateMcKesson Recalls Diltiazem CD Capsules Due to Dissolution Failures
FDA (Drugs) · 2018-05-02
- LowMcKesson Recalls Diltiazem HCl Extended-Release Capsules Due to Dissolution Failures
FDA (Drugs) · 2018-05-02
- ModerateMcKesson Recalls Diltiazem HCl Extended-Release Capsules Due to Dissolution Failures
FDA (Drugs) · 2018-05-02
- ModerateRanitidine Tablets Recalled for Failed Stability Specifications
FDA (Drugs) · 2018-03-14
- ModerateMcKesson Recalls Subpotent Megestrol Acetate Oral Suspension
FDA (Drugs) · 2018-02-14
Same hazard · quality failure
See all →- ModerateSirolimus Tablets Recalled for Failed Impurities and Degradation Specifications
FDA (Drugs) · 2021-09-29
- ModerateDr. Reddy's Atorvastatin Calcium Tablets Recalled for Failed Impurity Specifications
FDA (Drugs) · 2021-06-23
- SevereAuroMedics Recalls Acetaminophen Injection Due to Discoloration and pH Failures
FDA (Drugs) · 2021-02-10
- ModerateInvaGen Recalls Bupropion Hydrochloride Tablets for Dissolution Failures
FDA (Drugs) · 2018-04-11
- LowAkorn Recalls Atropine Sulfate Ophthalmic Solution Due to Viscosity Failure
FDA (Drugs) · 2018-03-14